Recent News

• 03.11.2025 - Leerink's Global Biopharma Conference 2025
• 03.06.2025 - scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
• 03.06.2025 - scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
• 03.05.2025 - TD Cowen 45th Annual Health Care Conference
• 02.26.2025 - scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
• 02.26.2025 - scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
• 02.05.2025 - scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
• 01.10.2025 - scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Recent Filings

• 02.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.31.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.28.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.10.2025 - 8-K Current report
• 01.10.2025 - EX-99.1 EX-99.1
• 01.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2024 - 10-Q/A Quarterly report [Sections 13 or 15(d)]
• 12.11.2024 - 8-K Current report